Below you'll find a list of all posts that have been categorized as “Kelso Pharma”
Kelso Pharma, the growing specialty pharma business backed by Apposite Capital, the healthcare specialist private equity investor, announces that it has secured over £140 million of acquisition funding and appointed former ADVANZ PHARMA CEO, Graeme Duncan, as Non-Executive Director.
Kelso Pharma, the growing specialty pharma business backed by Apposite Capital, the healthcare specialist private equity investor, today (19 February 2025) announces the acquisition of the UK pharma business, ALTURiX Holdings Limited (ALTURiX).
Kelso Pharma, the growing UK based specialty pharmaceuticals business, has appointed experienced pharma executive, John Rooper, as Director of Corporate Development as the company eyes further growth across international markets.
The acquisition of Italian specialty pharma company, Velit Biopharma (Velit), by UK-based specialty pharma business, Kelso Pharma (Kelso), announced on 13th November 2023, has now closed.
Kelso Pharma, the growing UK-based specialty pharma business, has concluded two new collaboration agreements with pharmaceuticals companies, PharmaPath and Valpharma.
Kelso Pharma (Kelso), the growing UK-based specialty pharma business, has taken its first step in its European expansion strategy by agreeing to acquire Italian specialty pharma company, Velit Biopharma (Velit).
Kelso Pharma, the growing UK-based specialty pharma business, has concluded a deal to acquire two UK approved products, representing an exciting launch into the specialty of Dermatology with prescription medicines for the treatment of actinic keratoses and plaque psoriasis.
Kelso Pharma, the growing UK based specialty pharma business, has announced its first product launch with the release to the UK prescription medicines market of Acepiro® (Acetylcysteine) 600mg effervescent tablets.
Kelso Pharma, the growing UK based specialty pharma business, has appointed senior pharmaceutical executive, Mark Inker, as its first UK Managing Director.
Kelso Pharma, the growing specialty pharma business, has appointed senior Life Sciences executive, Gordon Cameron OBE, as its Non-Executive Chairman. A senior executive with 25 years’ Board-level experience in private equity and plc listed businesses, Gordon has worked in the UK and US, primarily in biotech and pharmaceutical services including both contract research organisations (CRO) and contract development and manufacturing organisations (CDMO).
Apposite Capital, the healthcare specialist private equity investor, and Kelso Pharma today (12th January 2022) announce the acquisition of Stirling Anglian Pharmaceuticals Limited. Kelso Pharma is headed by Dr Tom Stratford, previously CEO of Kyowa Kirin International (“KKI”), the European and US business arm of Kyowa Kirin, which purchased Scottish Borders based ProStrakan Group PLC in 2011. He is joined …
Spreng Thomson: Intelligent Creative Communications
Spreng Thomson is committed to Fair Work, by ensuring that our people have an effective voice, by investing in their development and by not using zero hours contracts.
+44(0)141 548 5191
[email protected]
The Herald Building,
155 Albion Street,
Glasgow G1 1RU, UK
© 2025 Spreng Thomson Limited.
Registered in Scotland No. 173454
